查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602394

急性細菌性皮膚和結構性感染疾病市場：按感染類型、疾病類別、給藥途徑和分銷管道分類 - 全球預測 2025-2030

Acute Bacterial Skin & Skin Structure Infection Market by Infection Type (Community-Acquired ABSSI, Hospital Acquired ABSSI), Disease Category (Nonpurulent, Purulent), Route of Administration, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，急性細菌性皮膚和皮膚結構感染疾病市場估值為105.2億美元，預計到2024年將達到113.5億美元，複合年成長率為8.63%，到2030年預計將達到187.9億美元。

急性細菌性皮膚和皮膚結構感染疾病(ABSSSI) 涉及皮膚和皮下組織的嚴重細菌侵入，包括蜂窩性組織炎、傷口感染和膿腫等病症。這些感染疾病可能會迅速進展並引起併發症，需要及時有效的醫療干預。 ABSSSI 在醫療保健領域發揮重要作用，增加了先進抗生素和治療方法的需求。這些感染疾病的增加推動了對創新解決方案的需求，但它們的治療主要在醫院、診所和門診手術中心進行。市場動態是由抗藥性細菌發生率增加、醫學進步以及對新治療方法認知不斷增強等因素所驅動的。對新型抗生素不斷成長的需求以及對更好診斷工具的需求帶來了機遇，開發更快、更準確的診斷技術和下一代抗生素具有巨大潛力。抓住這些機會的建議包括投資新型抗生素的研發、與生技公司建立策略夥伴關係以及利用最尖端科技進行快速診斷。然而，市場面臨嚴格的監管途徑、高昂的藥物開發成本以及與抗生素治療相關的潛在副作用等限制，這可能會抑製成長。旨在對抗細菌抗藥性的嚴格抗生素管理計劃使市場滲透更加複雜。最好的創新領域是聯合治療的開發以及尋找抗藥性問題較少的天然或合成替代品。研究表明，製藥公司和研究機構之間的合作對於推動突破性解決方案至關重要。該市場競爭激烈，其特點是持續的研究工作、不斷變化的監管環境以及對具有成本效益的解決方案的需求。總體而言，技術創新對於解決 ABSSSI 未滿足的需求至關重要，公司必須平衡監管合規性、經濟可行性和有效的治療結果，才能在這個不斷發展的市場中取得成功。

主要市場統計
基準年[2023] 105.2億美元
預測年份 [2024] 113.5億美元
預測年份 [2030] 187.9億美元
複合年成長率（%） 8.63%

市場動態：針對快速發展的急性細菌性皮膚和皮膚結構感染疾病市場揭示的關鍵市場見解

供應和需求的動態相互作用正在改變急性細菌性皮膚和皮膚結構感染疾病市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 細菌性皮膚感染疾病的盛行率和案例不斷增加
    • 提高人們對皮膚問題的認知
    • 皮膚科中心和診所的增加
  • 市場限制因素
    • 與 ABSSSI 治療相關的不良健康影響
  • 市場機會
    • 開發新藥的持續研究開發活動
    • 臨床權威機構的監管核准迅速增加
  • 市場問題
    • 缺乏標準通訊協定和不正確的治療管理

波特的五力：駕馭急性細菌性皮膚和皮膚結構感染疾病市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解急性細菌性皮膚和皮膚結構感染疾病市場的外部影響

外部宏觀環境因素在塑造急性細菌性皮膚和皮膚結構感染疾病市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解急性細菌性皮膚和皮膚結構感染疾病市場的競爭格局

對急性細菌性皮膚和皮膚結構感染疾病市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：急性細菌性皮膚和皮膚結構感染疾病市場供應商的績效評估

FPNV 定位矩陣是評估急性細菌性皮膚和皮膚結構感染疾病市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製急性細菌性皮膚和皮膚結構感染疾病市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對急性細菌性皮膚和結構性感染疾病市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭格局中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 細菌性皮膚感染疾病的盛行率和病例不斷增加
      • 提高人們對皮膚問題的認知
      • 皮膚科中心和診所數量增加
    • 抑制因素
      • 與 ABSSSI 藥物相關的不良健康影響
    • 機會
      • 開發新藥的持續研究和開發活動
      • 臨床權威機構的監管核准迅速增加
    • 任務
      • 缺乏標準通訊協定和治療管理不充分
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章急性細菌性皮膚和皮膚結構感染疾病市場：依感染類型

  • 介紹
  • ABSSI 發生在社區
  • 院內ABSSI

第7章急性細菌性皮膚和皮膚結構感染疾病市場：依疾病類別

  • 介紹
  • 非化膿性
  • 化膿的

第8章急性細菌性皮膚和皮膚結構感染疾病市場：依給藥途徑

  • 介紹
  • 口服
  • 胃腸外的
  • 局部的

第9章急性細菌性皮膚和皮膚結構感染疾病市場：按分銷管道

  • 介紹
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章：美洲急性細菌性皮膚和皮膚結構感染疾病市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區急性細菌性皮膚和皮膚結構感染疾病市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章：歐洲、中東和非洲急性細菌性皮膚和皮膚結構感染疾病市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbvie, Inc.
  • Accord Healthcare Limited
  • Amneal Pharmaceuticals, Inc.
  • Aurobindo Pharma Limited
  • Basilea Pharmaceutica Ltd
  • BiVictriX Therapeutics PLC
  • Cadila Pharmaceuticals Limited
  • Cumberland Pharmaceuticals Inc.
  • Debiopharm SA
  • Destiny Pharma PLC
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Innovation Pharmaceuticals Inc.
  • Intas Pharmaceuticals Ltd.
  • KBP Biosciences Co., Ltd.
  • Melinta Therapeutics, LLC
  • Merck & Co, Inc
  • MicuRx Pharmaceuticals, Inc.
  • Novartis International AG
  • Paratek Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-B16853776E4F

The Acute Bacterial Skin & Skin Structure Infection Market was valued at USD 10.52 billion in 2023, expected to reach USD 11.35 billion in 2024, and is projected to grow at a CAGR of 8.63%, to USD 18.79 billion by 2030.

Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) involve serious bacterial invasion of skin and its underlying tissues, encompassing conditions like cellulitis, wound infections, and abscesses. These infections are critical due to their rapid progression and potential complications, demanding prompt and effective medical intervention. ABSSSIs hold crucial application in healthcare, driving the need for advanced antibiotics and therapies. Rising incidences of such infections fuel the necessity for innovative solutions, while their treatment primarily resides within hospitals, clinics, and ambulatory surgical centers. Market dynamics are propelled by factors like increasing incidence of drug-resistant bacteria, healthcare advancements, and heightened awareness around new treatment modalities. Opportunities arise from the growing demand for new antibiotics and the need for better diagnostic tools, with significant potential in developing faster and more accurate diagnostic technologies and next-generation antimicrobials. Recommendations for capturing these opportunities include investing in R&D for novel antimicrobial drugs, forming strategic partnerships with biotech firms, and leveraging cutting-edge technology for rapid diagnostics. However, the market faces limitations such as stringent regulatory pathways, high costs of drug development, and potential side effects associated with antibiotic treatments, which could dampen growth. Strict antibiotic stewardship programs to combat resistance further complicate market penetration. The best innovation areas lie in developing combination therapies and exploring natural or synthetic alternatives with fewer resistance issues. Insights suggest that collaborations between pharmaceutical companies and research institutions are essential to drive groundbreaking solutions. The market is competitive, characterized by ongoing research efforts, revolving regulatory landscape, and demand for cost-effective solutions. Overall, innovation will be crucial in addressing unmet needs in ABSSSIs, as companies need to balance between regulatory compliance, economic feasibility, and effective therapeutic outcomes to succeed in this evolving market.

KEY MARKET STATISTICS
Base Year [2023] USD 10.52 billion
Estimated Year [2024] USD 11.35 billion
Forecast Year [2030] USD 18.79 billion
CAGR (%) 8.63%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acute Bacterial Skin & Skin Structure Infection Market

The Acute Bacterial Skin & Skin Structure Infection Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence and cases of bacterial skin infections
    • Increasing people awareness about skin problems
    • Growth in number of dermatology centers and clinics
  • Market Restraints
    • Associated adverse health impacts of ABSSSI drugs
  • Market Opportunities
    • Ongoing R&D activities for development of novel drugs
    • Surge in regulatory approvals from clinical authorities
  • Market Challenges
    • Lack of standard protocols and mismanaged treatments

Porter's Five Forces: A Strategic Tool for Navigating the Acute Bacterial Skin & Skin Structure Infection Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acute Bacterial Skin & Skin Structure Infection Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acute Bacterial Skin & Skin Structure Infection Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acute Bacterial Skin & Skin Structure Infection Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acute Bacterial Skin & Skin Structure Infection Market

A detailed market share analysis in the Acute Bacterial Skin & Skin Structure Infection Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acute Bacterial Skin & Skin Structure Infection Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acute Bacterial Skin & Skin Structure Infection Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acute Bacterial Skin & Skin Structure Infection Market

A strategic analysis of the Acute Bacterial Skin & Skin Structure Infection Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acute Bacterial Skin & Skin Structure Infection Market, highlighting leading vendors and their innovative profiles. These include Abbvie, Inc., Accord Healthcare Limited, Amneal Pharmaceuticals, Inc., Aurobindo Pharma Limited, Basilea Pharmaceutica Ltd, BiVictriX Therapeutics PLC, Cadila Pharmaceuticals Limited, Cumberland Pharmaceuticals Inc., Debiopharm SA, Destiny Pharma PLC, Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Innovation Pharmaceuticals Inc., Intas Pharmaceuticals Ltd., KBP Biosciences Co., Ltd., Melinta Therapeutics, LLC, Merck & Co, Inc, MicuRx Pharmaceuticals, Inc., Novartis International AG, Paratek Pharmaceuticals, Inc., Pfizer Inc., Sun Pharmaceutical Industries Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Acute Bacterial Skin & Skin Structure Infection Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Infection Type, market is studied across Community-Acquired ABSSI and Hospital Acquired ABSSI.
  • Based on Disease Category, market is studied across Nonpurulent and Purulent.
  • Based on Route of Administration, market is studied across Oral, Parenteral, and Topical.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence and cases of bacterial skin infections
      • 5.1.1.2. Increasing people awareness about skin problems
      • 5.1.1.3. Growth in number of dermatology centers and clinics
    • 5.1.2. Restraints
      • 5.1.2.1. Associated adverse health impacts of ABSSSI drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D activities for development of novel drugs
      • 5.1.3.2. Surge in regulatory approvals from clinical authorities
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of standard protocols and mismanaged treatments
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Acute Bacterial Skin & Skin Structure Infection Market, by Infection Type

  • 6.1. Introduction
  • 6.2. Community-Acquired ABSSI
  • 6.3. Hospital Acquired ABSSI

7. Acute Bacterial Skin & Skin Structure Infection Market, by Disease Category

  • 7.1. Introduction
  • 7.2. Nonpurulent
  • 7.3. Purulent

8. Acute Bacterial Skin & Skin Structure Infection Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral
  • 8.4. Topical

9. Acute Bacterial Skin & Skin Structure Infection Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Acute Bacterial Skin & Skin Structure Infection Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Acute Bacterial Skin & Skin Structure Infection Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Acute Bacterial Skin & Skin Structure Infection Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie, Inc.
  • 2. Accord Healthcare Limited
  • 3. Amneal Pharmaceuticals, Inc.
  • 4. Aurobindo Pharma Limited
  • 5. Basilea Pharmaceutica Ltd
  • 6. BiVictriX Therapeutics PLC
  • 7. Cadila Pharmaceuticals Limited
  • 8. Cumberland Pharmaceuticals Inc.
  • 9. Debiopharm SA
  • 10. Destiny Pharma PLC
  • 11. Fresenius SE & Co. KGaA
  • 12. GlaxoSmithKline PLC
  • 13. Glenmark Pharmaceuticals Limited
  • 14. Innovation Pharmaceuticals Inc.
  • 15. Intas Pharmaceuticals Ltd.
  • 16. KBP Biosciences Co., Ltd.
  • 17. Melinta Therapeutics, LLC
  • 18. Merck & Co, Inc
  • 19. MicuRx Pharmaceuticals, Inc.
  • 20. Novartis International AG
  • 21. Paratek Pharmaceuticals, Inc.
  • 22. Pfizer Inc.
  • 23. Sun Pharmaceutical Industries Limited
  • 24. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET RESEARCH PROCESS
  • FIGURE 2. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET DYNAMICS
  • TABLE 7. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COMMUNITY-ACQUIRED ABSSI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY HOSPITAL ACQUIRED ABSSI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY NONPURULENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PURULENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET, FPNV POSITIONING MATRIX, 2023